Product Description
For intraocular Hypertension
Mechanisms of Action: Ion Channel Modulator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Danube
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Glaucoma|Hypertension|Angina Pectoris|Kidney Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2007-002208-17 | P2 |
Active, not recruiting |
Kidney Diseases|Angina Pectoris |
2008-12-14 |
|
DNB-001 | P2 |
Completed |
Glaucoma|Hypertension |
2008-08-01 |
|
2006-003907-38 | P2 |
Terminated |
Hypertension |
2007-12-12 |